Antigen-specific human monoclonal antibodies (mAbs) are key candidates for therapeutic
agents. However, the availability of a suitable screening system for antigen-specific antibody–…

Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of
immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. …

After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have
been developed for the prophylactic and therapeutic purposes. However, few methodologies …

The authors previously developed a cell‐microarray system that effectively detects antigen‐specific
B‐cells by monitoring intracellular Ca 2+ at single cell levels. Here they present a …

It is commonly understood that T cells are activated via trans interactions between antigen-specific
T-cell receptors (TCRs) and antigenic peptides presented on major histocompatibility …

The emergence of the SARS-CoV-2 Omicron variant is dominant in many countries worldwide.
The high number of spike mutations is responsible for the broad immune evasion from …

Antigen-specific T cell therapy, or T cell receptor (TCR) gene therapy, is a promising
immunotherapy for infectious diseases and cancers. However, a suitable rapid and direct screening …

Despite the growing knowledge of T cell responses in COVID-19 patients, there is a lack of
detailed characterizations for T cell-antigen interactions and T cell functions. Here, with a …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still rapidly spreading
worldwide. Many drugs and vaccines have been approved for clinical use show efficacy in the …

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its associated
receptors (TRAIL-R/TR) are attractive targets for cancer therapy because TRAIL induces …